AgomAb Therapeutics NV (AGMB) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precision BioSciences is the larger company by market cap ($282.5 million vs $268.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | DTIL |
|---|---|---|
| Share price | $5.45 | $7.40 |
| Market cap | $268.40M | $282.46M |
| 1-day change | -3.02% | +7.09% |
| YTD return | — | +77.88% |
| 1-year return | — | +48.00% |
| 5-year return | — | -97.23% |
| P/E ratio (TTM) | — | 29.60 |
| EPS (TTM) | $-2.08 | $0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $34.26M |
| Revenue growth (YoY) | — | -50.12% |
| Net income (latest FY) | — | $-45.72M |
| Operating margin | — | -152.19% |
| Net margin | — | -133.45% |
| 52-week high | $17.82 | $11.29 |
| 52-week low | $5.39 | $3.53 |
| Distance from 52-week high | -69.42% | -34.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +591.19% | +297.30% |
| Average volume | 208.99K | 319.79K |
| Shares outstanding | 49.25M | 38.17M |
| Employees | 62 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees
AGMB vs DTIL FAQ
Which is bigger, AgomAb Therapeutics NV or Precision BioSciences?
Precision BioSciences (DTIL) is larger, with a market capitalization of $282.46M compared with $268.40M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and Precision BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.